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ABSTRACT
Objective Maladaptive repair contributes towards the
development of heart failure following myocardial
infarction (MI). The αvβ3 integrin receptor is a key
mediator and determinant of cardiac repair. We aimed to
establish whether αvβ3 integrin expression determines
myocardial recovery following MI.
Methods 18F-Fluciclatide (a novel αvβ3-selective
radiotracer) positron emission tomography (PET) and CT
imaging and gadolinium-enhanced MRI (CMR) were
performed in 21 patients 2 weeks after ST-segment
elevation MI (anterior, n=16; lateral, n=4; inferior, n=1).
CMR was repeated 9 months after MI. 7 stable patients
with chronic total occlusion (CTO) of a major coronary
vessel and nine healthy volunteers underwent a single
PET/CT and CMR.
Results 18F-Fluciclatide uptake was increased at sites
of acute infarction compared with remote myocardium
(tissue-to-background ratio (TBRmean) 1.34±0.22 vs
0.85±0.17; p<0.001) and myocardium of healthy
volunteers (TBRmean 1.34±0.22 vs 0.70±0.03;
p<0.001). There was no 18F-fluciclatide uptake at sites
of established prior infarction in patients with CTO, with
activity similar to the myocardium of healthy volunteers
(TBRmean 0.71±0.06 vs 0.70±0.03, p=0.83).
18F-Fluciclatide uptake occurred at sites of regional wall
hypokinesia (wall motion index≥1 vs 0; TBRmean
0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and
subendocardial infarction. Importantly, although there
was no correlation with infarct size (r=0.03, p=0.90) or
inflammation (C reactive protein, r=−0.20, p=0.38),
18F-fluciclatide uptake was increased in segments
displaying functional recovery (TBRmean 0.95±0.33 vs
0.81±0.27, p=0.002) and associated with increase in
probability of regional recovery.
Conclusion 18F-Fluciclatide uptake is increased at sites
of recent MI acting as a biomarker of cardiac repair and
predicting regions of recovery.
Trial registration number NCT01813045; Post-results.
INTRODUCTION
Ischaemic heart disease remains the leading cause
of death globally, with over 1 million people suffer-
ing acute myocardial infarction (MI) per year in the
USA alone. As the acute management of MI
improves, the number of patients surviving acute
myocardial injury is higher than ever before. In this
population, adverse cardiac remodelling and the
syndrome of delayed heart failure represent the
major cause of morbidity.1 Understanding repara-
tive mechanisms following infarction is becoming
increasingly important.
Repair following MI is triggered by a complex inter-
action of neurohormonal activation and upregulation
of angiogenic and pro-fibrotic transcription factors
that initiate the restoration of a capillary network
through angiogenesis and re-endothelialisation, as well
as extracellular matrix (ECM) remodelling through
macrophage accumulation and fibroblast activation.
This interplay of angiogenesis, inflammation and
fibrosis determines the extent of preservation and
restoration of myocardial integrity.2 In some cir-
cumstances, maladaptive persistent processes may
encourage remodelling and scarring to extend into
the myocardium long after the initial causative
injury. This may lead to progressive ventricular dila-
tation, ventricular dysfunction and heart failure.
The αvβ3 integrin is a transmembrane cell surface
receptor that facilitates migration, proliferation and
interaction with the ECM, thereby allowing cells to
respond to, and in turn modify, their extracellular
environment. Expressed at low levels by quiescent
endothelial cells, αvβ3 integrin is markedly upregu-
lated in states of angiogenesis within the myocar-
dium after infarction.3 4 In addition, preclinical
and clinical studies document αvβ3 integrin expres-
sion by both activated cardiac myofibroblasts and
macrophages during margination and chemotaxis.
Thus, αvβ3 integrin expression appears central to
the coordination of repair following MI.
In this study, we investigated the expression of
αvβ3 integrin following MI using the novel αvβ3
integrin-selective radiotracer, 18F-fluciclatide, com-
bined with cardiac positron emission tomography
(PET), CT and cardiovascular MRI (CMR). The
study aims to describe and characterise the uptake
of this radiotracer and to correlate it with clinical
markers of disease severity and functional recovery
in patients with recent MI.
METHODS
PET/CT scanning with 18F-fluciclatide and CMR
were performed in three groups of participants
recruited from Royal Infirmary of Edinburgh
between July 2013 and February 2015. Exclusion
criteria were age <40 years, women of childbearing
potential not taking contraception, severe renal
failure (serum creatinine >2.8 mg/dL) or hepatic
failure (Child-Pugh grade B or grade C), atrial
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fibrillation, contrast allergy, inability to undergo scanning and
inability to provide informed consent. Studies were performed
with approval of the local research ethics committee, in accord-
ance with the Declaration of Helsinki, and with the written
informed consent of each participant.
Study participants
Acute MI group
Patients with recent acute ST-segment elevation MI and peak
high-sensitivity cardiac troponin I (hs-cTnI) >10 000 ng/L were
invited to attend PET/CT scanning with 18F-fluciclatide
14±7 days after their initial presentation. CMR was performed
within 7 days of PET/CT scanning. Patients were then invited to
return for a second PET/CT scan with 18F-fluciclatide 10 weeks
after MI and for a follow-up CMR at 9 months.
Chronic total occlusion group
Patients with an angiographically documented complete occlu-
sion of a major epicardial artery and stable cardiac symptoms
for >6 months were invited to attend for a single PET/CT scan
with 18F-fluciclatide and CMR.
Control group
Volunteers with normal left ventricular (LV) systolic function,
no structural heart disease and no symptoms of heart failure or
MI underwent a single PET/CT scan with 18F-fluciclatide and
CMR.
Histology cohort
For histological analysis, myocardial biopsy samples were
obtained from patients undergoing coronary artery bypass graft-
ing following recent MI. Patients with large ST-elevation MI
(<14 days, hs-cTnI >10 000 ng/L) were considered for inclu-
sion, forming a separate cohort from the acute MI group.
Radiosynthesis of 18F-fluciclatide
The radiotracer was manufactured at the Clinical Research
Imaging Centre, University of Edinburgh on an automated
module (FASTlab synthesizer; GE Healthcare) by coupling an
amino-oxy-functionalised peptide precursor (AH111695) with
4-18F-fluorobenzaldehyde at pH 3.5 to form 18F-fluciclatide.
Full description of this synthesis has been published.5–7
Imaging assessments
All patients underwent PET-CT imaging of the thorax with a
hybrid scanner (Biograph mCT, Siemens Medical Systems,
Germany) after administration of a target dose of 230 MBq
18F-fluciclatide (see online supplementary material). No dietary
restrictions were required prior to radiotracer administration.
Attenuation-correction CT scanning (non-enhanced 120 kV and
50 mA, 3 mm slices) was performed, followed by PET acquisi-
tion with ECG gating. To assess tracer pharmacodynamics and
the optimum timing of scanning, dynamic thoracic PET imaging
was initially performed in 10 subjects in three-dimensional
mode with a single-bed position for 70 min. The remainder of
study subjects underwent static imaging performed at the
optimal time point as determined from the dynamic studies
(40 min post-injection) using a single 30 min bed position in list
mode. Immediately after PET acquisition, cardiac CT angiog-
raphy was performed on the hybrid scanner (see online
supplementary material).
PET reconstruction and analysis
Kinetic analysis of the dynamic scans was undertaken to in-
vestigate 18F-fluciclatide uptake within the myocardium (see
online supplementary material). For all patients, static
ECG-gated PET images were reconstructed in diastole,
40–70 min post-injection. Myocardial 18F-fluciclatide uptake
was assessed by an experienced observer (WSAJ) by drawing
regions of interest (ROIs) in each myocardial segment using
the standardised 16-segment approach.8 Additionally, ROIs
were drawn in focal regions affected by infarction and in
regions of remote myocardium. This was achieved using the
fused CT angiography and CMR images as a reference and with
care taken to avoid contamination from the blood pool signal.
PET data were corrected for residual blood pool activity (stand-
ard uptake value, SUV) in the superior vena cava and expressed
as a mean tissue-to-background ratio (TBRmean). SUVmax and
TBRmax values were also calculated alongside the corrected
SUV values, where blood pool activity was subtracted from
myocardial uptake (see online supplementary material).
CMR imaging
CMR with assessment of late gadolinium enhancement (LGE) and
T1 mapping was performed at 3 T (MAGNETOM Verio, Siemens
AG, Healthcare Sector, Germany) with calculation of LV function,
wall motion index (WMI), transmurality of LGE and extracellular
volume (ECV) fraction (see online supplementary material).
Histology
Briefly, a core cardiac biopsy was taken from the peri-infarct
zone, fresh-frozen and sectioned in cryosection medium (see
online supplementary material). Adjacent tissue sections were
stained with HE for conventional, smooth muscle actin, CD31,
CD68 (clone PG-M1) and integrin αvβ3 antibody clone LM609
(Millipore) before digital imaging (Axioscan.Z1, Zeiss, UK) and
histopathological examination.
Statistical analysis
We explored myocardial radiotracer uptake in three groups of
patients, comparing them with CMR and clinical indices of
cardiac function. Continuous data were tested for normality
with the D’Agostino and Pearson Omnibus test. Continuous
normal variables were expressed as mean±SD and compared
using Student’s t-test or analysis of variance test when compar-
ing more than two groups. Continuous non-normal variables
were presented as median (IQR) and compared using the
Mann-Whitney or Kruskal-Wallis test when evaluating two or
more than two groups. Interobserver reproducibility was calcu-
lated by Bland-Altman method and presented as mean bias ±2
SDs and intraclass correlation coefficients (ICC) with 95% CI.
The χ2 test was used for analysis of categorical variables.
Univariable and multivariable logistic regression models were
used to determine factors associated with an improvement in
segmental myocardial function. Statistical analysis was per-
formed with GraphPad Prism (V.6; GraphPad Software, USA)
and JMP (V.10.0; SAS Software, North Carolina, USA), where
appropriate. A two-sided p value<0.05 was considered statistic-
ally significant.
RESULTS
A total of 37 subjects underwent PET/CT after injection of
229±12 MBq 18F-fluciclatide: 21 patients with acute MI,
7 patients in the chronic total occlusion (CTO) group and nine
healthy volunteers (tables 1 and 2). The groups were generally
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well balanced for age, sex and body mass index. Healthy sub-
jects had a lower prevalence of cardiovascular risk factors
(table 1). The mean radiation dose per participant for those
who received a single PET/CT imaging assessment was
13.6 mSv (range 7.8–18.9 mSv) and 21.9 mSv (range 16.5–
28.7 mSv) in those who underwent repeat PET scanning.
CMR characterisation of MI and remodelling
There were no areas of infarction in control subjects. All
patients within the acute MI cohort (n=21) had visible infarc-
tion on CMR 13±5 days after MI. These infarcts were large
(infarct size 12±7 g/m2, peak cTnI 50 000 ng/L (26 753–
50 000 ng/L)) and featured the anterior (n=16) and lateral
(n=4) territories predominantly, while one patient had an infer-
ior MI. All subjects received emergency coronary angiography
with successful revascularisation 197 min (148–342 min) from
the onset of symptoms (see online supplementary table S1).
Old infarcts were present in six of seven patients in the CTO
group. Although there was no difference in infarct size (g/m2)
between MI and CTO groups (p=0.34), the LV ejection fraction
(LVEF) was reduced with a larger WMI score in those with
recent MI (p<0.01 compared with either the CTO or control
group, table 2).
Seventeen patients from the acute MI group received
follow-up CMR imaging 287±37 days after MI. During this
timeframe, there were improvements in LVEF (p<0.01) and
regional wall motion (WMI; p<0.005). In total, 43 of 272 myo-
cardial segments (16%) showed an improvement in regional
wall motion, while 226 segments remained unchanged and
three segments displayed functional deterioration. Infarct size
and LV mass also improved (p=0.03 and p<0.01 respectively,
table 3).
Histology and dynamic myocardial 18F-fluciclatide PET
In an exploratory analysis, two patients scheduled for coronary
artery bypass surgery within 14 days of infarction underwent
myocardial biopsies from the peri-infarct zone (figure 1). This
showed predominantly viable myocardium with widespread
positive staining for αvβ3 integrin, largely in regions that
co-localised to CD31-positive vascular endothelial cells.
Interestingly, these sites represented mainly angiogenic microvas-
culature, although there was scattered co-localisation with dual
smooth muscle actin- and CD31-positive arterioles. There were
Table 1 Baseline participant characteristics
All
(n=37)
Acute myocardial infarction group
(n=21)
Chronic total occlusion group
(n=7)
Control group
(n=9) p Value*
Patient characteristics
Age (years) 64±10 62±12 69±7 66±7 0.06
Male sex 27 (73) 16 (76) 5 (71) 6 (67) 0.46
BMI (kg/m2) 28±4 28±5 31±3 27±4 0.74
18F-Fluciclatide dose (mBq) 229±12 227±13 227±14 232±9 0.86
Current smoker 9 (24) 8 (38) 1 (14) 0 (0) 0.01
Diabetes mellitus 4 (11) 3 (14) 1 (14) 0 (0) 0.06
Hypertension 16 (43) 7 (33) 5 (71) 4(44) 0.04
Hypercholesterolaemia 22 (60) 14 (66) 6 (86) 2 (22) <0.001
Cardiovascular history
Prior myocardial infarction 7 (19) 1 (5) 6 (86) 0 (0) <0.001
Angiographically documented CAD 28 (76) 21 (100) 7 (100) 0 (0) <0.001
Previous PCI 4 (11) 1 (5) 3 (42) 0 (0) <0.001
CCS class
0 28 (76) 17 (81) 2 (29) 9 (100) 0.02
I or II 7 (19) 4 (19) 3 (42) 0 (0) 0.03
III or IV 2 (6) 0 (0) 2 (29) 0 (0) 0.51
NYHA class
I 29 (78) 15 (71) 3 (42) 9 (100) 0.32
II 7 (19) 5 (24) 2 (29) 0 (0) 0.39
III or IV 2 (6) 1 (5) 1 (14) 0 (0) 0.25
Medications
Aspirin 27 (73) 21 (100) 6 (86) 0 (0) <0.001
Clopidogrel 22 (59) 19 (90) 3 (42) 0 (0) <0.001
Statin 29 (78) 21 (100) 7 (100) 1 (11) 0.004
β-blocker 26 (70) 20 (95) 6 (86) 0 (0) <0.001
ACEi/ARB 27 (73) 20 (95) 5 (71) 2 (22) 0.02
Clinical features
Systolic BP (mm Hg) 137±22 128±18 140±24 155±21 0.06
Heart rate (bpm) 64±12 62±13 61±11 68±10 0.42
Creatinine (mmol/L) 79±15 82±19 77±14 73±12 0.54
hs-CRP (mg/L) 3.5 (1.3–9.8) 5.6 (2.0–11.7) 2.2 (1.0–9.1) 1.5 (1.2–3.3) 0.008
*Analysis of variance, Student’s t-test (continuous data) or χ2 test (categorical data).
Mean±SD, median (IQR) or number (percentage).
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; hs-CRP,
high-sensitivity C reactive protein; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
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lesser numbers of CD68-positive inflammatory cells and smooth
muscle actin-positive myofibroblasts, but where present, these
also co-registered with αvβ3 integrin expression (figure 1).
Dynamic PET studies were performed in a subgroup of 10
patients. 18F-Fluciclatide activity within the region of MI
increased gradually and reached a plateau at around 30–40 min
(figure 2). The injected activity was cleared from the blood pool
with a half-life of about 10 min, so that it remained relatively
high during the period of PET acquisition (superior vena cava
SUVmean 2.73±0.51 at 40–70 min post-injection). The optimum
contrast between 18F-fluciclatide uptake in the site of infarction
and the blood pool was observed at 40 min (figure 2B). This
time point was therefore used for subsequent static imaging.
Using a two-compartment Patlak model,5 18F-flucicatide
uptake displayed a distinct linear phase and a steep Ki slope, in
keeping with irreversible binding of 18F-fluciclatide to αvβ3
integrin during the 70 min period of evaluation (figure 2D).
The three-dimensional parametric images generated from Patlak
analysis (figures 2E and 3F and see online supplementary
video 1) confirmed regions of increased 18F-fluciclatide binding
in sites of acute infarction, supporting an upregulation of αvβ3
integrin within the infarct zone.
Static 18F-fluciclatide PET in MI
Using static PET images, the interobserver reproducibility asses-
sing 18F-fluciclatide uptake in the myocardium was good (see
online supplementary table S2). Briefly, quantifying focal uptake
in acute infarction was most reproducible using the TBRmean
method, showing no fixed or proportional biases (mean % dif-
ference 3.0 (95% CI −24.0 to 29.9)) and a high ICC value
(0.94 (95% CI 0.83 to 0.98)). This measure was therefore pref-
erentially used for subsequent analysis. Quantification of the
regional 18F-fluciclatide TBRmean in individual myocardial seg-
ments also proved reproducible with no fixed or proportional
biases (mean % difference −8.97 (95% CI −31.6 to 13.6)) and
a high ICC value (0.90 (95% CI 0.590 to 0.975), see online
supplementary table S3).
All patients in the acute MI cohort had increased focal myocar-
dial uptake of 18F-fluciclatide on baseline PET/CT scanning (12
±4 days after MI), which co-localised to regions of infarction on
CMR (figures 2 and 3, tables 2 and 3, see online supplementary
videos 1 and 2). Hepatic uptake of 18F-fluciclatide was common.
However, in the patient with inferior MI, basal inferior and infer-
oseptal myocardial uptake of 18F-fluciclatide was quantifiable.
18F-Fluciclatide uptake was greater in the acute myocardial infarct
Table 2 Baseline imaging assessment
All
(n=37)
Acute myocardial infarction group
(n=21)
Chronic total occlusion group
(n=7)
Control group
(n=9) p Value*
CMR imaging
LVEF (%) 58±10 52±9 62±8 65±5 <0.001
LV mass (indexed, g/m2) 79±20 85±20 66±17 75±16 0.07
LVEDV (mL/m2) 77±18 80±18 69±13 76±17 0.35
LVESV (mL/m2) 34±13 39±14 30±10 27±9 0.046
WMI 0.25±0.13 0.40±0.20 0.09±0.05 0.0±0.0 <0.001
ECV (%) 31±5 34±4 28±3 28±2 <0.001
Presence of LGE 27 (73) 21 (100) 6 (86) 0 (0) <0.001
Infarct size (g/m2) 8±8 12±7 8±8 0±0 <0.001
PET imaging
SUVmean (kBq/mL)
SVC 2.73±0.51 2.85±0.51 2.57±0.39 2.58±0.57 0.27
Total LV uptake 2.24±0.51 2.33±0.48 1.96±0.53 1.77±0.27 <0.001
Myocardial infarct uptake 3.23±1.03 3.72±0.63 1.76±0.26 – <0.001
Remote myocardial uptake 2.21±0.60 2.41±0.57 1.62±0.14 – 0.001
TBRmean
Total LV uptake 0.77±0.16 0.82±0.18 0.71±0.06 0.70±0.03 0.08
Myocardial infarct uptake 1.05±0.37 1.34±0.22 0.70±0.14 – <0.001
Remote myocardial uptake 0.80±0.18 0.85±0.17 0.64±0.12 – 0.009
SUVmax (kBq/mL)
Total LV uptake 2.71±0.58 2.86±0.56 2.24±0.40 2.07±0.31 <0.001
Myocardial infarct uptake 3.53±1.00 3.98±0.68 2.18±0.35 – <0.001
Remote myocardial uptake 2.59±0.64 2.75±0.65 2.18±0.35 – 0.02
TBRmax
Total LV uptake 0.98±0.19 1.02±0.19 0.89±0.20 0.81±0.09 0.01
Myocardial infarct uptake 1.28±0.34 1.42±0.25 0.86±0.16 – <0.001
Remote myocardial uptake 0.94±0.19 0.97±0.20 0.84±0.13 – 0.11
SUVC (kBq/mL)
Total LV uptake −0.55±0.57 −0.52±0.55 −0.61±0.67 0.81±0.42 0.85
Myocardial infarct uptake 0.75±0.91 1.13±0.67 −0.40±0.46 – <0.001
Remote myocardial uptake −0.19±0.52 −0.11±0.54 −0.45±0.37 – 0.12
*Analysis of variance, Student’s t-test (continuous data) or χ2 test (categorical data).
Mean±SD or number (percentage).
CMR, cardiac magnetic resonance; ECV, extracellular volume; LGE, late gadolinium enhancement; LV, left ventricular; LVEDV, LV end diastolic volume; LVEF, LV ejection fraction; LVESV, LV
end systolic volume; PET, positron emission tomography; SUV, standardised uptake value; SUVC, corrected SUV; SUVmax, maximum SUV; SVC, superior vena cava; TBR, tissue-to-background
ratio; WMI, wall motion index.
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when compared with regions of old infarction in the CTO cohort
and healthy myocardium in the control group, regardless of the
measure of PET uptake used (eg, TBRmean 1.34±0.22 vs 0.70
±0.14 vs 0.70±0.10, p<0.001 respectively). Indeed, no focal
increase in 18F-fluciclatide uptake was observed in regions of
chronic infarction, with similar PET uptake measurements com-
pared with control subjects (eg, TBRmean, p=0.83). In regions of
myocardium remote to the site of acute infarction, 18F-fluciclatide
activity was modestly but uniformly increased when compared
with comparative regions in patients with CTO (TBRmean 0.85
±0.17 vs 0.64±0.12, p=0.009). Across our population, there
were no age-related (TBRmean, r=−0.19 (−0.53–0.19), p=0.31)
or sex-related (TBRmean 1.14±0.07 vs 1.25±0.17, p=0.46)
differences in 18F-fluciclatide uptake.
Table 3 Acute MI assessments
Imaging data
CMR imaging Initial CMR (n=21) Follow-up CMR (n=17) p Value
MI to CMR (days) 13±5 287±37 <0.01
LVEF (%) 52±9 55±8 <0.01
Indexed LV mass (g/m2) 85±20 74±13 <0.01
LVEDV (mL/m2) 80±18 82±16 0.88
LVESV (mL/m2) 39±14 38±12 0.36
Wall motion index 0.40±0.20 0.22±0.15 <0.01
ECV (%) 34±4 33±2 0.58
Infarct size (g/m2) 13 (7–17) 6 (3–14) 0.03
PET imaging
Initial PET/CT (n=21) Repeat PET/CT (n=17)
MI to PET (days) 12±4 76±19 <0.01
Total LV uptake (TBRmean) 0.82±0.18 0.85±0.18 0.96
Myocardial infarct uptake (TBRmean) 1.34±0.22 1.20±0.21 0.02
Remote myocardial uptake (TBRmean) 0.85±0.17 0.82±0.15 0.38
Segmental uptake (TBRmean) and regional WMI
Normal function (0) 0.80±0.26 0.83±0.23 0.14
Mild-mod hypokinesia (1) 0.89±0.33 0.97±0.29 0.33
Severe hypokinesia (2) 0.97±0.28 0.91±0.34 0.47
Akinesia (3) 0.77±0.21 0.73±0.24 0.66
Dyskinesia (4) – – –
Segmental uptake and transmurality of MI (TBRmean)
No infarct 0.75±0.23 0.81±0.23 NA
Subendocardial infarct (1–75%) 0.95±0.29 1.08±0.28 NA
Transmural infarct (76–100%) 0.89±0.29 0.88±0.27 NA
Mean±SD or median (IQR).
CMR, cardiac magnetic resonance; ECV, mean extracellular volume; LV, left ventricle; LVEDV, LV end diastolic volume; LVEF, LV ejection fraction; LVESV, LV end systolic volume; MI,
myocardial infarction; PET, positron emission tomography; TBRmean, mean tissue-to-background ratio; WMI, wall motion index.
Figure 1 αvβ3 integrin expression in patient with recent myocardial infarction (MI). Adjacent fresh-frozen and cryosectioned biopsies from the
peri-infarct area of a patient with recent anterior MI are shown. Immunohistochemical staining for (A) αvβ3 integrin displayed multiple regions of
positive staining that co-localise to regions of staining for vascular endothelial cells (CD31), (B) visible at ×4 magnification. At ×20 magnification,
these regions of αvβ3 staining (C) correspond predominantly to arterioles and the microvasculature (D) and also to regions of staining for smooth
muscle actin (SMA) (E), representative of both arterioles (co-staining with CD31) and myofibroblasts. There were relatively few macrophages (F).
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Seventeen subjects agreed to return for a second
18F-fluciclatide PET/CT 76±19 days post-MI, with similar
results noted. All these patients were clinically stable between
the scans. 18F-Fluciclatide uptake remained elevated at the site
of infarction (MI vs CTO group, TBRmean 1.20±0.21 vs 0.70
±0.15 respectively, p<0.001), although the intensity was
reduced compared with earlier imaging (p=0.01; figure 3).
Increased 18F-fluciclatide uptake also persisted in regions of
remote myocardium when compared with uptake in patients
with CTO (TBRmean 0.82±0.15 vs 0.64±0.12 respectively,
p=0.01) and interestingly remained equivalent in terms of
intensity compared with the initial PET scan (TBRmean 0.85
±0.17 vs 0.82±0.15 respectively, p=0.38).
Myocardial 18F-fluciclatide uptake and cardiac function
The extent of 18F-fluciclatide uptake following MI was com-
pared with clinical and imaging measures of MI severity and
subsequent repair (see online supplementary table S3). Although
segmental 18F-fluciclatide uptake displayed a moderate correl-
ation with the degree of ECV on CMR T1 mapping (r=0.37,
p<0.001), it did not correlate with many of the standard mea-
sures of infarct severity; in particular, there were no associations
with infarct size on CMR (r=0.03, p=0.90), LVEF (r=−0.08,
p=0.72), hs-cTnI (r=0.13, p=0.36) or C reactive protein
(r=−0.20, p=0.38) (see online supplementary table S3). This
may be explained by the absence of increased uptake in the
largest akinetic infarcts (normal wall motion vs akinetic seg-
ments; TBRmean 0.80±0.26 vs 0.77±0.21, p=0.77). Rather,
18F-fluciclatide activity was highest in segments with hypokinesis
(WMI 1&2 vs 0; TBRmean 0.92±0.03 vs 0.80±0.26, p<0.001;
figure 4) and segments associated with a subendocardial pattern
of LGE (subendocardial LGE vs no LGE; TBRmean 0.95±0.06
vs 0.75±0.03 respectively, p<0.001; figure 4).
18F-Fluciclatide uptake was higher in hypokinetic regions that
subsequently demonstrated functional recovery compared with
regions with no change or a worsening in contractile function
(TBRmean 0.95±0.33 vs 0.81±0.02 respectively, p=0.002;
figure 4, see online supplementary video 2). Using logistic
regression analysis, 18F-fluciclatide TBRmean emerged as a pre-
dictor of recovery in segmental cardiac function on univariable
analysis (OR 1.27 (95% CI 1.08 to 1.50) per 10% increase in
TBRmean, p=0.003), which persisted after adjustment for age
and sex (OR 1.27 (95% CI 1.07 to 1.51) per 10% increase in
TBRmean, p=0.005). This effect was however attenuated follow-
ing additional adjustment for the transmurality of LGE (OR
1.03 (95% CI 0.83 to 1.26) per 10% increase in TBRmean,
p=0.80) and ECV (OR 1.02 (0.91 to 1.32) per 10% increase in
TBRmean, p=0.35).
DISCUSSION
Using the novel radiotracer 18F-fluciclatide, we have for the first
time described the temporal expression of myocardial αvβ3
Figure 2 Dynamic analysis of 18F-fluciclatide uptake is shown. Axial and sagittal CT angiographies of the thorax in a patient with recent anterior
myocardial infarction (A) are shown. The time-activity curves generated from the descending aorta and the apical interventricular septum (blue
crosshairs) show increased uptake in the infarct relative to blood pool. Optimal contrast between 18F-fluciclatide tissue and blood pool activity was
observed after 40 min (dotted line, B). The positron emission tomography image in the axial and sagittal plane shows increased uptake within the
apical septum, although there is some background activity (C). Patlak analysis of regions of interests placed in the interventricular septum confirms
integrin binding, as evidenced by the gradient of the slope and the y-intercept (D) and, using a Ki-generated image, we can better identify and
delineate focal uptake within myocardium (E). A region of remote myocardium within the same patient generates a Patlak curve with significantly
lower gradient and intercept in comparison (F).
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integrin receptor in patients with recent acute MI. We demon-
strate intense early uptake attributable to regions of recent
infarction, in particular subendocardial, hypokinetic infarcts
that appeared to demonstrate subsequent functional recovery.
Our data suggest that αvβ3 integrin receptor expression can be
readily quantified in the infarct zone and that 18F-fluciclatide
PET may hold promise as a clinical biomarker of healing activity
with application to novel pharmacological or cell-based therap-
ies aimed at improving outcome after MI.
Expression of αvβ3 integrin by vascular endothelial cells facili-
tates myocardial salvage through angiogenesis in the peri-infarct
zone, while also mediating the activated macrophage response
to inflammatory signals and governing myofibroblast differenti-
ation through the activation of latent transforming growth
factor-β1.9–11 The αvβ3 integrin contains a binding site for an
RGD peptide subunit (the arginine-glycine-aspartate motif ) and
this is the target for a number of molecular imaging probes. In
murine and human studies of acute MI, RGD-based radiotracers
accumulate at the site of infarction as early as 3 days, peaking at
1–3 weeks post-MI4 12 and correlating with adverse remodelling
and infarct scar formation at 12 months.13 14 For the first time,
we have here confirmed and extended these findings using
the highly selective and sensitive PET RGD-radiotracer,
18F-fluciclatide. Moreover, given the study sample size and com-
prehensive imaging assessment, we have been able to make
several significant observations as well as incorporate a number
of important controls and comparisons.
We have compared 18F-fluciclatide uptake in patients with
recent acute MI with healthy control subjects and patients with
established infarction. We have demonstrated that 18F-fluciclatide
uptake is specific for acute infarction and does not bind to old
established infarcts. Perhaps more importantly, we did not see a
correlation with acute infarct size, quantified as the mass of LGE
on CMR. Indeed binding of 18F-fluciclatide in akinetic infarcts
was relatively low and was instead highest in subendocardial
infarcts associated with hypokinesia. This would suggest that
18F-fluciclatide uptake is not a surrogate of infarction but relates
more to the tissue-healing response to injury.
There are a number of potential explanations for the preferen-
tial binding of 18F-fluciclatide to subendocardial infarcts. It is pos-
sible that microvascular obstruction in larger infarcts prevented
tissue penetration by 18F-fluciclatide or that the presence of tissue
necrosis resulted in loss of tissue architecture. However, a
number of our observations suggest that 18F-fluciclatide uptake
reflects novel αvβ3 integrin expression due to re-endothelialisation
and angiogenesis in the peri-infarct zone. First, ex-vivo histo-
logical examination 2 weeks following MI demonstrated that αvβ3
integrin expression predominantly co-localises within endothelial
cells of the microvasculature. Second, increased 18F-fluciclatide
uptake was associated with functional recovery of hypokinetic
infarcts. Third, we did not observe 18F-fluciclatide uptake in
patients with CTO who have chronic and well-established collat-
eral vasculature. Fourth, we did not observe large regions of
microvascular obstruction on CMR imaging. This suggests that
only newly forming vessels or repopulation of vessels with endo-
thelial cells will result in αvβ3 integrin expression and
18F-fluciclatide uptake. This is consistent with similar observations
in other diseased states such as angiogenesis associated with
malignancy.5 7 In our patients with MI, intense binding was
observed in the peri-infarct regions of subendocardial MIs with
only poorly defined uptake in the central necrotic area. Given
these associations and the likelihood that 18F-fluciclatide identifies
areas of re-endothelialisation and angiogenesis, it is perhaps not
surprising that 18F-fluciclatide uptake appeared to localise to seg-
ments that demonstrated subsequent functional recovery. Taken
together, our data suggest that assessing αvβ3 integrin expression
in the acute phase of repair might be of use in investigating the
Figure 3 18F-Fluciclatide uptake in acute myocardial infarction (MI)
is shown. 18F-Fluciclatide uptake in three patients with recent
subendocardial MI is shown. Patient 1, 13 days after anterior MI,
displaying a short-axis positron emission tomography (PET) image of
the left ventricle with crescentic 18F-fluciclatide uptake (A) that
correlates with the interventricular septum and anterior wall on CT
angiography (B). The fused PET/CT-angiography image (C) shows this
uptake to correspond exactly with the region of late gadolinium
enhancement (LGE) on cardiac magnetic resonance (CMR) (D). Further
delineation of myocardial uptake on PET/CT is clearer in the
two-chamber view (E) and on a fused CT/three-dimensional-Patlak
image, which shows this uptake to follow a watershed-pattern
emerging from the coronary stents present in the left anterior
descending coronary artery (F) (see online supplementary video file 1).
(G) and (H) Patient 2, 8 days following anterior MI, displaying focal
uptake of 18F-fluciclatide in the anterior wall and apex in the
three-chamber view on PET/CT (G) which corresponds to the region of
infarction on LGE CMR imaging (H). (I) and (J) Patient 3, showing focal
uptake of 18F-fluciclatide in the inferior wall 19 days following MI on
PET/CT (I) that again corresponds to the infarction on CMR LGE
imaging ( J).
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healing processes that occur following acute MI. Larger studies
are required to confirm these initial findings and assess whether
18F-fluciclatide PET provides incremental benefit to CMR (our
study was not sufficiently powered). However, as a marker of
activity, 18F-fluciclatide may be of particular use in assessing the
effects of novel therapies aimed at accelerating repair post-MI.
At 10 weeks following MI, 18F-fluciclatide uptake persisted in
the region of infarction but was reduced compared with the
2-week assessment. This delayed phase of repair is characterised
pathologically by a reduction in inflammation and angiogenesis
and a more moderated reorganisation of the ECM through
myofibroblast-driven type I and type III collagen production.15
From our study, we are unable to determine whether this reduc-
tion in 18F-fluciclatide uptake reflects the waning of
re-endothelialisation and angiogenesis or represents a switching
to myofibroblast cell types indicative of an enhanced fibrotic
response. There was some heterogeneity in the time course of
18F-fluciclatide uptake since uptake increased at 10 weeks in six
subjects. However, we detected no adverse effects of this
increase in uptake and there was no corresponding increase in
LGE or ECVon T1 mapping.
Modification of the ECM following MI is limited to the site
of infarction. Indeed, the myofibroblast-driven fibrotic expan-
sion seen in the remote myocardium influences global myocar-
dial recovery.16 Expression of αvβ3 integrin in remote
myocardial regions has been reported up to 6 months following
MI.10 17 In keeping with this, 18F-fluciclatide activity was con-
sistently increased in the remote myocardium at both 2 and
10 weeks when compared with comparative myocardial regions
in patients with CTO and healthy controls.
There are some limitations in our study that we should
acknowledge. First, despite accounting for systolic motion using
ECG gating, cardiac PET is also limited by respiratory motion
and this may affect sensitivity in particular due to the high activ-
ity in the closely adjacent blood pool and hepatic tissue. This is
likely to be a particular problem for inferior infarcts (present in
only one of our study subjects), although these less commonly
lead to adverse remodelling and heart failure. Novel motion
tracking may in the future help to negate some of these issues
and enable even greater definition of regional αvβ3 integrin
expression.18 Second, limited cardiac tissue was available for
histological assessment, preventing complete stoichiometric and
temporal assessment of αvβ3 integrin expression in humans
post-MI. Fortunately, inference can be drawn from extensive
animal models of infarction but, for future application of
18F-fluciclatide, a more extensive histological assessment would
be preferred. Third, our study was not powered to address the
incremental value of 18F-fluciclatide PET over established pre-
dictor markers of cardiac recovery such as CMR. This will
require larger patient populations. Instead this study provides
the first description of increased 18F-fluciclatide in the myocar-
dium following MI, indicating that it provides important infor-
mation about the LV remodelling response. Further studies will
be required to establish the clinical utility of this approach.
In conclusion, we report the largest and most comprehensive
analysis of an αvβ3 integrin radiotracer in the assessment of
Figure 4 18F-Fluciclatide uptake in myocardial infarction (MI) is shown. Uptake of 18F-fluciclatide in (A) patients with acute MI at 2 and
10 weeks, patients with chronic total occlusion and healthy control subjects is shown. Uptake was greatest at 2 weeks after MI (B). 18F-Fluciclatide
uptake in the acute MI group was greater in regions of hypokinesis when compared with sites of normal function or akinesis (C). This translated to
a higher 18F-fluciclatide uptake in those regions which subsequently improved in function on follow-up cardiac magnetic resonance (D). CTO,
chronic total occlusion; TBR, tissue-to-background ratio. WMA, wall motion abnormality.
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myocardial repair following acute MI. We have demonstrated
that increased 18F-fluciclatide uptake occurs at sites of acute MI,
in particular regions of subendocardial infarction and hypokine-
sia associated with subsequent functional recovery. Our data
suggest that myocardial αvβ3 integrin expression represents a
marker of ongoing cardiac repair and that 18F-fluciclatide is a
potentially useful imaging biomarker for investigating this
healing response post-MI.
Key messages
What is already known on this subject?
Non-invasive imaging of myocardial remodelling may permit
understanding, prediction and potential modification of adverse
remodelling and the syndrome of delayed heart failure following
myocardial infarction (MI). The αvβ3 integrin cell surface
receptor is intrinsic to angiogenesis, inflammation and
fibrogenesis in remodelling myocardium and has been targeted
using positron emission tomography (PET) radiotracers in murine
and small human studies following MI. However, the role of
αvβ3 integrin radiotracers in humans following MI is
incompletely defined.
What might this study add?
Using PET imaging with kinetic analysis, CT contrast
angiography and cardiac MRI, we have demonstrated that
18F-fluciclatide binds with αvβ3 integrin receptors in regions of
acute MI and in the remote myocardium. 18F-fluciclatide uptake
correlates with functional impairment and may predict
myocardial recovery.
How might this impact on clinical practice?
Our study fulfils a key step validating αvβ3 integrin receptor
imaging in humans following MI. This novel characterisation of
myocardial remodelling may hold potential as a biological end
point in the study of novel therapies following MI.
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Acknowledgements The authors acknowledge the support of staff at Edinburgh
Heart Centre at Royal Infirmary of Edinburgh; radiography and radiochemistry staff of
the Clinical Research Imaging Centre and histology staff (Mike Miller and Lindsey
Boswell) at the Queens Medical Research Institute.
Contributors All authors have contributed significantly to the submitted work.
DEN, MRD, WSAJ, IW, AF, CL, EJRvB and JHFR undertook the conception and
design of the study and the collection, analysis and interpretation of the data was
undertaken by WSAJ, ATV, MC, AN, CM, AV, TP, CS and SM. The drafting of the
manuscript and its revision was completed by WSAJ, ATV, MRD and DEN. All
authors have read and approved the manuscript as written.
Funding 18F-Fluciclatide FASTlab materials were provided by General Electric
Healthcare. The study and MRD, WSAJ and DEN are supported by the British Heart
Foundation (FS/12/84, FS/10/026, CH/09/002, RM/13/2/30158, RE/13/3/30183).
DEN is the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA).
JHFR is part-funded by the National Institute for Health Research Cambridge
Biomedical Research Centre. The Wellcome Trust Clinical Research Facility and
Clinical Research Imaging Centre are supported by NHS Research Scotland through
NHS Lothian.
Competing interests None declared.
Patient consent Obtained.
Ethics approval South East Scotland Research Ethics Committee 2.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Unpublished data are available on request in keeping
with the data-sharing legislation of the University of Edinburgh.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure
in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol
2003;42:1446–53.
2 Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction.
Circulation 2000;101:2981–8.
3 Meoli DF, Sadeghi MM, Krassilnikova S, et al. Noninvasive imaging of myocardial
angiogenesis following experimental myocardial infarction. J Clin Invest
2004;113:1684–91.
4 Higuchi T, Bengel FM, Seidl S, et al. Assessment of v 3 integrin expression after
myocardial infarction by positron emission tomography. Cardiovasc Res
2008;78:395–403.
5 Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting
Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
J Nucl Med 2008;49:879–86.
6 McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation
dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl
Med 2008;49:1664–7.
7 Tomasi G, Kenny L, Mauri F, et al. Quantification of receptor-ligand binding with
[18F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging
2011;38:2186–97.
8 Cerqueira MD, Weissman NJ, Dilsizian V, et al., American Heart Association Writing
Group on Myocardial Segmentation and Registration for Cardiac Imaging.
Standardized myocardial segmentation and nomenclature for tomographic imaging
of the heart. A statement for healthcare professionals from the Cardiac Imaging
Committee of the Council on Clinical Cardiology of the American Heart Association.
Circulation 2002;105:539–42.
9 Sarrazy V, Koehler A, Chow ML, et al. Integrins αvβ5 and αvβ3 promote latent
TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc Res
2014;102:407–17.
10 Sun M, Opavsky MA, Stewart DJ, et al. Temporal response and localization of
integrins beta1 and beta3 in the heart after myocardial infarction: regulation by
cytokines. Circulation 2003;107:1046–52.
11 Antonov AS, Antonova GN, Munn DH, et al. αVβ3 integrin regulates macrophage
inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation. J Cell
Physiol 2011;226:469–76.
12 Sun Y, Zeng Y, Zhu Y, et al. Application of (68)Ga-PRGD2 PET/CT for
αvβ3-integrin imaging of myocardial infarction and stroke. Theranostics
2014;4:778–86.
13 Sherif HM, Saraste A, Nekolla SG, et al. Molecular imaging of early αvβ3 integrin
expression predicts long-term left-ventricle remodeling after myocardial infarction in
rats. J Nucl Med 2012;53:318–23.
14 Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial
changes in patients after myocardial infarction: comparison with delayed
contrast-enhanced magnetic resonance imaging. J Nucl Cardiol
2010;17:1065–72.
15 Plein S, Kidambi A. Understanding LV remodeling following myocardial infarction.
J Am Coll Cardiol 2012;5:894–6.
16 Carrick D, Haig C, Rauhalammi S, et al. Pathophysiology of LV remodeling in
survivors of STEMI: inflammation, remote myocardium, and prognosis. JACC
Cardiovasc Imaging 2015;8:779–89.
17 van den Borne SWM, Diez J, Blankesteijn WM, et al. Myocardial remodeling after
infarction: the role of myofibroblasts. Nat Rev Cardiol 2010;7:30–7.
18 Rubeaux M, Joshi NV, Dweck MR, et al. Motion correction of 18F-sodium fluoride
PET for imaging coronary atherosclerotic plaques. J Nucl Med 2016;57:54–9.
Jenkins WSA, et al. Heart 2016;0:1–9. doi:10.1136/heartjnl-2016-310115 9
Coronary artery disease
group.bmj.com on December 13, 2016 - Published by http://heart.bmj.com/Downloaded from 
acute myocardial infarction in humans
 integrin expression following3βVαCardiac 
van Beek, Saeed Mirsadraee, Marc R Dweck and David E Newby
Alison Fletcher, Tania Pawade, Ian Wilson, James H F Rudd, Edwin J R
Christophe Lucatelli, Anoushka Neale, Catriona Moles, Anna Vickers, 
William S A Jenkins, Alex T Vesey, Colin Stirrat, Martin Connell,
 published online December 7, 2016Heart 
 http://heart.bmj.com/content/early/2016/12/07/heartjnl-2016-310115
Updated information and services can be found at: 
These include:
References
 #BIBL
http://heart.bmj.com/content/early/2016/12/07/heartjnl-2016-310115
This article cites 18 articles, 11 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (213)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on December 13, 2016 - Published by http://heart.bmj.com/Downloaded from 
